Biologics company adds Dr. Michael May to board

Eric Oliver -   Print  |

Biologics development company AgeX Therapeutics added Michael May, PhD, to its board of directors, returning it to full strength.

Dr. May replaced an independent board member who recently left the board. He is the president and CEO of Canada's Centre for Commercialization of Regenerative Medicine and is heavily involved in the biologics space. He helped the Centre raise more than $100 million, which supported spinoff companies and helped develop academic partnerships.

AgeX Therapeutics board chairman Greg Bailey, MD, lauded the hiring, referring to Dr. May as a "globally-recognized leader in regenerative medicine."

More articles on biologics:
Dr. Robert Brady: Robotics in spinal fusion and how the trend will develop in spine
Orthofix names DePuy, Medtronic, Biomet veteran the next CEO
Medicrea receives FDA approval for new screw device

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers